A team from the Institute of Cancer Research, London, found NXP800 slowed the growth of prostate cancer cells, including those that had developed a resistance to hormone therapy
A team from the Institute of Cancer Research, London, found NXP800 slowed the growth of prostate cancer cells, including those that had developed a resistance to hormone therapy